Not available
Quote | Reata Pharmaceuticals Inc. (NASDAQ:RETA)
Last: | $172.36 |
---|---|
Change Percent: | 0.01% |
Open: | $172.34 |
Close: | $172.36 |
High: | $172.46 |
Low: | $172.32 |
Volume: | 1,988,594 |
Last Trade Date Time: | 09/25/2023 03:00:00 am |
News | Reata Pharmaceuticals Inc. (NASDAQ:RETA)
2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Message Board Posts | Reata Pharmaceuticals Inc. (NASDAQ:RETA)
Subject | By | Source | When |
---|---|---|---|
Good news recently, we should start to see this one move | Whalatane | investorshub | 05/09/2023 6:30:59 PM |
$RETA Long and strong lets hope im right | rynlrt | investorshub | 05/09/2023 2:36:15 PM |
Looks pretty positive | IPO$ | investorshub | 05/02/2023 5:05:07 PM |
Price gaining last up | rynlrt | investorshub | 05/01/2023 6:13:11 PM |
$RETA short data if anyone is interested | IPO$ | investorshub | 05/01/2023 5:22:30 PM |
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023